Additionally, the use of liposomal RNA vaccines targeting melanoma-associated antigens NY-ESO-1, MAGE-A3, tyrosinase, and TPTE, have shown efficacy in melanoma tumor regression as monotherapy or in combination. This evidence concerns the gene TPTE and neoplasm.